Evidence map›Paper›PMID 33811165›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2021

Automated Quantitative Measures of Terminal Duct Lobular Unit Involution and Breast Cancer Risk-Letter.

Amy C Degnim, Derek C Radisky, Celine M Vachon, Mark E Sherman

Abstract readLetterComment
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Amy C DegnimDivision of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, Minnesota. degnim.amy@mayo.edu.ORCID 0000-0002-2303-4946
Derek C RadiskyDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida.
Celine M VachonDivision of Epidemiology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-1962-9322
Mark E ShermanDepartment of Health Science Research, Mayo Clinic, Jacksonville, Florida.

Funding

Molecular Discriminators in Benign Breast Tissue for Future Risk of ER positive aR01CA187112 · NCI · MAYO CLINIC ROCHESTER · PI DEGNIM, AMY C · 2014 to 2018
$2.9M
Involution-based biomarkers of breast cancer riskR01CA237602 · NCI · MAYO CLINIC JACKSONVILLE · PI DEGNIM, AMY C, RADISKY, DEREK C · 2020 to 2024
$2.8M
NCI NIH HHS R01 CA187112NCI NIH HHS R01 CA237602
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsMammary Glands, HumanBreastFemaleHumansRisk

Identifiers

PMID33811165
PMCPMC9473338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.